[go: up one dir, main page]

CA2326695A1 - Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c - Google Patents

Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c Download PDF

Info

Publication number
CA2326695A1
CA2326695A1 CA002326695A CA2326695A CA2326695A1 CA 2326695 A1 CA2326695 A1 CA 2326695A1 CA 002326695 A CA002326695 A CA 002326695A CA 2326695 A CA2326695 A CA 2326695A CA 2326695 A1 CA2326695 A1 CA 2326695A1
Authority
CA
Canada
Prior art keywords
nucleic acid
acid molecule
hcv
ribozyme
enzymatic nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002326695A
Other languages
English (en)
Inventor
Lawrence Blatt
James A. Mcswiggen
Beth Roberts
Pamela A. Pavco
Dennis Macejak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirna Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/274,553 external-priority patent/US20020082225A1/en
Application filed by Individual filed Critical Individual
Publication of CA2326695A1 publication Critical patent/CA2326695A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention se rapporte à des molécules d'acides nucléiques enzymatiques qui modulent l'expression et/ou la réplication du virus de l'hépatite C.
CA002326695A 1998-04-27 1999-04-26 Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c Abandoned CA2326695A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US8321798P 1998-04-27 1998-04-27
US60/083,217 1998-04-27
US10084298P 1998-09-18 1998-09-18
US60/100,842 1998-09-18
US25760899A 1999-02-25 1999-02-25
US09/257,608 1999-02-25
US09/274,553 US20020082225A1 (en) 1999-03-23 1999-03-23 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis c virus infection
US09/274,553 1999-03-23
PCT/US1999/009027 WO1999055847A2 (fr) 1998-04-27 1999-04-26 Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c

Publications (1)

Publication Number Publication Date
CA2326695A1 true CA2326695A1 (fr) 1999-11-04

Family

ID=27491784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002326695A Abandoned CA2326695A1 (fr) 1998-04-27 1999-04-26 Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c

Country Status (8)

Country Link
EP (1) EP1075508A2 (fr)
JP (1) JP2002512791A (fr)
KR (1) KR20010043111A (fr)
CN (1) CN1312856A (fr)
AU (1) AU757034B2 (fr)
CA (1) CA2326695A1 (fr)
ID (1) ID28053A (fr)
WO (1) WO1999055847A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
BR0308923A (pt) * 2002-03-27 2005-01-04 Aegera Therapeutics Inc OligÈmeros de nucleobase de iap anti-sentido e empregos destes
KR100490699B1 (ko) * 2002-10-05 2005-05-19 제노프라 주식회사 씨형 간염 바이러스의 아이알이에스 발현 세포에서만 선택적으로 유전자 활성을 유도하는 트랜스-스플라이싱 리보자임
JP2007518425A (ja) * 2004-01-23 2007-07-12 バイオメリュー・インコーポレイテッド Ｈｃｖ３’非翻訳領域を効率的に増幅および検出するためのプライマーおよびプローブの設計

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus

Also Published As

Publication number Publication date
WO1999055847A2 (fr) 1999-11-04
WO1999055847A3 (fr) 2000-06-15
JP2002512791A (ja) 2002-05-08
EP1075508A2 (fr) 2001-02-14
AU757034B2 (en) 2003-01-30
KR20010043111A (ko) 2001-05-25
CN1312856A (zh) 2001-09-12
ID28053A (id) 2001-05-03
AU3665799A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
US6127173A (en) Nucleic acid catalysts with endonuclease activity
US6602858B2 (en) Nucleic acid catalysts comprising L-nucleotide analogs
WO2002081494A1 (fr) Inhibition regulee par des oligonucleotides de la replication du virus de l'hepatite b et du virus de l'hepatite c
AU748176B2 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
WO2002068637A2 (fr) Traitement a base d'acide nucleique de maladies ou d'etats pathologiques associes a une infection par le virus du nil occidental
US6797815B2 (en) Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
WO1998043993A2 (fr) Acides nucleiques en tant que catalyseurs
US20040127446A1 (en) Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US20040054156A1 (en) Method and reagent for inhibiting hepatitis B viral replication
US20030171311A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
AU3974001A (en) Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
WO1998050530A9 (fr) Traitement a l'acide nucleique enzymatique de maladies et etats pathologiques associes aux niveaux d'expression de c-raf
US20030068301A1 (en) Method and reagent for inhibiting hepatitis B virus replication
US20030125270A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
AU757034B2 (en) Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
EP1165758A2 (fr) Regulation de genes represseur avec des molecules d'acide nucleique
US6656731B1 (en) Nucleic acid catalysts with endonuclease activity
AU757789B2 (en) Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses
US20020082225A1 (en) Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis c virus infection
US20020013458A1 (en) Enzymatic nucleic acid treatment of disases or conditions related to hepatitis c virus infection
WO2002011674A2 (fr) Procede et reactif permettant d'inhiber le canal chlorure active par le calcium 1 (clca-1)
WO2001062911A2 (fr) Methode et reactif d'inhibition de grid
AU2002258610A1 (en) Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication

Legal Events

Date Code Title Description
FZDE Dead